Selected Announcement of A-share Market | WuXi AppTec (603259.SH): First repurchase of about 100 million yuan, cumulative repurchase of 1.035 million shares.

Focus today 1. Boe Technology Group: Listed on the "Chinese Military Enterprise List" by the U.S. Department of Defense without legitimate reasons Boe Technology Group announced that the company has noticed the release of the "Chinese Military Enterprise List" by the U.S. Department of Defense on June 8, 2026, which includes Boe. The company stated that it is neither a Chinese military enterprise nor a military-civilian integration enterprise in China's national defense industry, and there is no legitimate reason for being included in the list. Currently, the company's production and operation are normal, with all business steadily progressing. The restrictions on the list are only related to U.S. defense procurement and do not prohibit anyone else from conducting business with the company. 2. Xinlian Integrated Circuit: Plans to invest 3.012 billion yuan in a 12-inch automotive-grade chip manufacturing project Xinlian Integrated Circuit announced that the company plans to cooperate with Hangzhou Regional Cooperation to invest in Xinlian Advanced Integrated Circuit Manufacturing (Shaoxing) Co., Ltd., as the main implementer of the 12-inch automotive-grade mixed-signal chip manufacturing project. They will build a 12-inch integrated circuit automotive-grade mixed-signal chip production line with a monthly capacity of 50,000 pieces, focusing on 40/28 nanometer MCU/DSP, 90/55 nanometer BCD/DrMOS analog circuits, 55 nanometer silicon photonics/laser drivers, and other chips. The project's total investment is approximately 20 billion yuan, with 12 billion yuan in capital, and Xinlian Integrated Circuit plans to invest 3.012 billion yuan. After this investment is completed, the company's stake in Xinlian Advanced will decrease from 100% to 25.1%. 3. WuXi AppTec: Plans for the first repurchase of about 100 million yuan, accumulating repurchases of 1.035 million shares WuXi AppTec announced that the company previously disclosed plans to repurchase company A shares worth 1 billion yuan for employee stock ownership plans, with a repurchase price limit of 156.95 yuan per share. On June 11, 2026, the company implemented its first repurchase, repurchasing 1.0352 million shares through centralized bidding, accounting for 0.0347% of the total share capital. The repurchase price range was from 95.59 yuan per share to 97.54 yuan per share, with a total fund amount of approximately 100 million yuan (excluding transaction fees). 4. Henan Carve Electronics Technology: Plans to acquire not less than 51% equity of Dongguan Qinding and Dongguan Xingding, entering the liquid-cooled heat dissipation track Henan Carve Electronics Technology announced that the company plans to acquire not less than 51% equity of Dongguan Qinding Hardware Products Co., Ltd., and Dongguan Xingding Hardware Products Co. Ltd in cash. After the transaction is completed, the company will achieve controlling interest and consolidate the financial statements. With the vigorous development of the global computing power center and industries like artificial intelligence, the target company has seen a rapid increase in orders from relevant customers. This acquisition will help the company expand its international market, attract more overseas customers, deepen its layout in the data center industry, enter the liquid-cooled heat dissipation track, and cultivate new profit growth points. 5. Foshan Blue Rocket Electronics: Plans to acquire 60% equity of Chengdu Xinyi for 336 million yuan, and audit evaluation has been completed Foshan Blue Rocket Electronics announced that the company signed an Equity Acquisition Intention Agreement with part of the shareholders of Chengdu Xinyi Technology Co., Ltd. on January 12, 2026. As of now, the audit and evaluation of the target company has been completed, and the company plans to acquire 60% of Chengdu Xinyi for 336 million yuan in cash or self-raised funds. Once the transaction is completed, Chengdu Xinyi will become the company's subsidiary and be included in the consolidated financial statements. The transaction has been approved by the company's 15th board meeting of the fifth session and still needs to be submitted for approval by the company's shareholders' meeting. The performance commitment party has committed to the target company's net profit for the years 2026, 2027, and 2028 not to be less than 33 million yuan, 40 million yuan, and 47 million yuan respectively, with a total net profit commitment of not less than 120 million yuan over three years. 6. Suzhou Gyz Electronic Technology: MLCC business is still in a loss state Suzhou Gyz Electronic Technology announced that the company's stock price has risen by 254.83% between April 12, 2026, and June 11, 2026. The company's stock price deviates significantly from the market index, with a high risk of speculation due to large short-term fluctuations. As of June 11, 2026, the latest rolling price-earnings ratio for the "C39 computer, communication, and other electronic (881123) equipment manufacturing" industry where the company belongs is 62.23 times. The company's net profit attributable to shareholders of the listed company for 2025 was negative, resulting in no price-earnings multiple. The company faces the risk of being overvalued, with overheated market sentiment and irrational speculation, potentially leading to a significant correction. The company's operating performance is influenced by various factors such as macroeconomic conditions, downstream market development trends, the competitiveness of the company's products, and customer recognition, and has a certain level of uncertainty. The company's MLCC business requires significant initial capital investment, has a long investment cycle, and is still in a loss state. 7. Zhejiang Wolwo Bio-Pharmaceutical: Withdraws the clinical trial application for the "Human Umbilical Cord Mesenchymal Stem Cell II Injection" Zhejiang Wolwo Bio-Pharmaceutical announced that its indirectly-controlled subsidiary Zhejiang Womu Stem Cell Technology Co., Ltd. obtained the "Notice of Termination of Drug Registration Application" from the National Medical Products Administration Drug Evaluation Center and agreed to withdraw the clinical trial application for the "Human Umbilical Cord Mesenchymal Stem Cell II Injection." During the technical evaluation process of this product, the National Medical Products Administration Drug Evaluation Center communicated with the drug registration applicant and found that some pharmaceutical research needed to be improved. Based on cautious consideration, the drug registration applicant withdrew the application. After completing the relevant pharmaceutical research, the drug registration applicant will resubmit the clinical trial application for the product as soon as possible. 8. Jiangsu Yoke Technology: Currently, there is no business related to tungsten hexafluoride Jiangsu Yoke Technology announced that the company's stock trading price has deviated more than 20% from the closing price for two consecutive trading days (June 10 and 11, 2026), which is considered abnormal market volatility. The company mainly focuses on the electronic materials business and LNG insulation board business. The company has noted recent discussions online about the company's specialty gas business, specifically mentioning the company's specialty gas products, mainly tetrafluoromethane and sulfur hexafluoride. The company does not have any tungsten hexafluoride-related business currently. In 2025, the revenue from the company's specialty gas business accounted for 5.79% of the company's total revenue. The company advises investors to make rational decisions and invest cautiously. 9. Shanghai Anlogic Infotech: Shareholders' Great Fundi... (Unfortunately, the text is too long for a single response. Please let me know if you'd like me to continue with the translation.)